While discussion of the advantages of PSA testing had an association with increased screening, discussion of the disadvantages of PSA testing had no association with reduced screening, suggesting that any discussion of PSA testing likely occurs in the context of a clinician- or patient-initiated effort to ultimately screen for prostate cancer. The gene discussed is KLK3; the disease is prostate carcinoma.